{'fraction_non_alphanumeric': 0.012903225806451613, 'fraction_numerical': 0.007526881720430108, 'mean_word_length': 5.795620437956204, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
PB2132 DARATUMUMAB MONOTHERAPY FOR RELAPSED AND REFRACTORY MULTIPLE MYELOMA REAL CLINICAL PRACTICE. A MULTICENTRIC RETROSPECTIVE STUDY

Daratumumab is intended to be used as a monotherapy for the treatment of relapsed or refractory multiple myeloma following three or more prior lines of treatment. If licensed, daratumumab will offer an additional treatment option for this patient group. Patients who experience relapse after treatment with lenalidomide and bortezomib have a particularly poor prognosis. Daratumumab is a humanised IgG1K monoclonal antibody targeted at CD38, an antigen highly expressed in multiple myeloma cells. Through binding to this antigen, daratumumab mediates the activation of antibody-dependent cellular and complement-dependent cytotoxicity to stimulate the immune system to more effectively kill tumour cells. Daratumumab does not currently have Marketing Authorisation in the EU for any indication.